GenRx CLOMIPRAMINE TABLETS

NAME OF THE MEDICINE
Clomipramine hydrochloride

Chemical Name: 3-chloro-5-[3-(dimethylamino)-propyl]-10, 11-dihydro-5H dibenz [b,f] azepine hydrochloride.

Structural Formula:

![Structural Formula](image)

Molecular Formula: C₁₉ H₂₃ N₂Cl . HCl
Molecular Weight: 351.3
CAS Registry Number: 17321-77-6

DESCRIPTION
Clomipramine is the 3-chloro derivative of imipramine. It is a white crystalline powder, soluble in water, slightly soluble in ethanol and insoluble in diethyl ether.

PHARMACOLOGY

Pharmacodynamics
Clomipramine is a tricyclic antidepressant. It inhibits the neuronal re-uptake of noradrenaline (NA) and serotonin (5-HT) released in the synaptic cleft, inhibition of 5-HT uptake being the dominant component of this activity. Clomipramine also has a wide spectrum of pharmacological action, including alpha₁-adrenolytic, anticholinergic, antihistaminic and antiserotonergic (5-HT-receptor blocking) properties.

Pharmacokinetics
Absorption
The active substance is completely absorbed following oral administration, but due to extensive hepatic first pass metabolism to the active metabolite, N-desmethylclomipramine, less than 50% of a dose reaches the systemic circulation unchanged.

During oral administration of constant daily doses of clomipramine, the steady-state plasma concentrations of clomipramine show wide variations between patients. Administration of the standard dose recommended for treatment of depression, i.e. 25 mg clomipramine orally three times daily, produced steady state concentrations ranging from 31 ng/mL to 186 ng/mL. This scatter reflects differences in clomipramine’s distribution volume and clearance between individuals. Variations in concentration in any one patient are much less than those between patients.

The steady-state concentrations of the active metabolite, N-desmethyliclomipramine follow a similar pattern. On average, they range 68–334 ng/mL at a dose of 75 mg clomipramine per day.
The plasma clearance of clomipramine in elderly patients is lower than in patients in intermediate age groups. As a result, elderly patients require smaller doses of clomipramine.

**Distribution**
Clomipramine is highly (97.6%) bound to serum proteins. Its distribution and elimination follow two-compartment kinetics, with a beta-phase half-life of 21 hours (range 12–36 hours). The principle metabolite, N-desmethylclomipramine, has a beta-phase half-life in the range of 13–25 hours.

In the cerebrospinal fluid the concentration is equivalent to about 2% of the plasma concentration.

The distribution volume of unchanged clomipramine is approximately 12 L/kg body weight.

**Metabolism**
The primary route of clomipramine metabolism is demethylation to form the active metabolite, N-desmethylclomipramine. N-desmethylclomipramine can be formed by several P450 enzymes, primarily CYP3A4, CYP2C19 and CYP1A2. Clomipramine and N-desmethylclomipramine are hydroxylated to form 8-hydroxyclomipramine or 8-hydroxy-N-desmethylclomipramine. The activity of the 8-hydroxy metabolites are not defined in vivo. Clomipramine is also hydroxylated at the 2-position and N-desmethylclomipramine can be further demethylated to form didesmethylclomipramine. The 2- and 8-hydroxy metabolites are excreted primarily as glucuronides in the urine. Elimination of the active components, clomipramine and N-desmethylclomipramine, by formation of 2- and 8-hydroxy clomipramine is catalysed by CYP2D6.

**Excretion**
Two-thirds of a single dose of clomipramine is excreted in the form of water-soluble conjugates in the urine and about one-third in the faeces. The quantity of unchanged clomipramine and N-desmethylclomipramine excreted in the urine amounts in each instance to less than 1% of the dose administered.

**INDICATIONS**
- Major depression.
- Obsessive-compulsive disorders and phobias in adults.
- Cataplexy associated with narcolepsy.

**CONTRAINDICATIONS**
- Known hypersensitivity to clomipramine and any of the excipients in the tablets.
- Cross-hypersensitivity to tricyclic antidepressants of the dibenzazepine group.
- Concomitant use with a monoamine oxidase (MAO) inhibitor, or within 14 days before or after treatment with an irreversible MAO inhibitor, or within 14 days before moclobemide, a reversible MAO inhibitor (see PRECAUTIONS, Interactions with Other Medicines).
- Acute and recovery stages of myocardial infarction.
- Congenital long QT syndrome.

**PRECAUTIONS**

**Clinical Worsening and Suicide Risk**
The risk of suicide attempt is inherent in depression and may persist until significant remission occurs. This risk must be considered in all depressed patients.

Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications and this risk may persist until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases.
Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset or was not part of the patients presenting symptoms. Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. Patients with co-morbid depression associated with other psychiatric disorders being treated with antidepressants should be similarly observed for clinical worsening and suicidality.

Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are at greater risk of suicidal thoughts or suicidal attempts and should receive careful monitoring during treatment.

Pooled analyses of 24 short-term (4 to 16 weeks), placebo-controlled trials of nine antidepressant medicines (SSRIs and others) in 4,400 children and adolescents with major depressive disorder (16 trials), obsessive compulsive disorder (4 trials) or other psychiatric disorders (4 trials) have revealed a greater risk of adverse events representing suicidal behaviour or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients treated with an antidepressant was 4% compared with 2% of patients given placebo. There was considerable variation in risk among the antidepressants, but there was a tendency towards an increase for almost all antidepressants studied. The risk of suicidality was most consistently observed in the major depressive disorder trials, but there were signals of risk arising from trials in other psychiatric indications (obsessive compulsive disorder and social anxiety disorder) as well. No suicides occurred in these trials. It is unknown whether the suicidality risk in children and adolescents patients extends to use beyond several months. The nine antidepressant medicines in the pooled analyses included five SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) and four non-SSRIs (bupropion, mirtazapine, nefazodone, venlafaxine).

Pooled analysis of short-term studies of antidepressant medications have also shown an increased risk of suicidal thinking and behaviour, known as suicidality, in young adults (aged 18–24) during initial treatment, generally the first one to two months. Short-term studies did not show an increase in the risk of suicidality with antidepressants, compared to placebo, in adults older than the age of 24 years; there was a reduction with antidepressants, compared to placebo, in adults aged 65 years and older.

Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania have been reported in adults, adolescents and children being treated with antidepressants for major depressive disorder, as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either worsening of depression and/or emergence of suicidal impulses has not been established, there is concern that such symptoms may be precursors of emerging suicidality.

Families and caregivers of children and adolescents being treated with antidepressants for major depressive disorder or for any other conditions (psychiatric or non-psychiatric) should be informed about the need to monitor these patients for the emergence of agitation, irritability, unusual changes in behaviour and other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. It is particularly important that monitoring be undertaken during the initial few months of antidepressant treatment or at times of dose increase or decrease.

Prescriptions for clomipramine should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

**Caution in the following circumstances:**
Caution is called for when employing tricyclic antidepressants in patients with -

- Cardiovascular insufficiency, atrioventricular block (grades I to III) and arrhythmias. Monitoring of cardiovascular function and the ECG is required in such patients, especially in the elderly. Myocardial infarction, precipitation of congestive cardiac failure, stroke and sudden death have been reported with drugs of this class.

- A history of increased intraocular pressure, narrow-angle glaucoma.
Disorders of micturition due to an impeded flow of urine (e.g. in diseases of the prostate).

A low convulsion threshold (e.g. due to brain damage of varying aetiology; epilepsy; concomitant use of other drugs, such as neuroleptics, that may lower seizure threshold; and withdrawal from alcohol or drugs with anticonvulsive properties, such as benzodiazepines). The occurrence of seizures seems to be dose-dependent. Therefore, the recommended daily dose of clomipramine should not be exceeded.

Severe hepatic or renal disease.

Patients with tumours of the adrenal medulla (e.g. phaeochromocytoma, neuroblastoma), in whom the drug may provoke hypertensive crises.

Hyperthyroidism, or concomitant treatment with thyroid preparations, since aggravation of unwanted cardiac effects can generally be expected to occur owing to the anticholinergic action.

Chronic constipation, as tricyclic antidepressants may cause paralytic ileus, particularly in elderly and bed-ridden patients.

**QTc Prolongation**

There may be a risk of QTc prolongation and Torsades de pointes, particularly at supra-therapeutic doses or supra-therapeutic plasma concentrations of clomipramine, as occur in the case of co-medication with selective serotonin reuptake inhibitors (SSRIs) or serotonin and noradrenergic reuptake inhibitors (SNRIs). Therefore, concomitant administration of drugs that can cause accumulation of clomipramine should be avoided (see PRECAUTIONS, Interactions with Other Medicines). Equally, concomitant administration of drugs that can prolong the QTc interval should be avoided. It is established that hypokalaemia is a risk factor for QTc prolongation and Torsades de pointes. Therefore, hypokalaemia should be treated before initiating treatment with clomipramine. Clomipramine should be used with caution when combined with diuretics (see PRECAUTIONS, Interactions with Other Medicines).

**Serotonin Syndrome**

Due to the risk of serotonergic toxicity, it is advisable to adhere to recommended doses of clomipramine. Serotonin syndrome, with symptoms such as hyperpyrexia, myoclonus, agitation, seizures, delirium and coma, can possibly occur when clomipramine is co-administered with serotonergic medications such as SSRIs, SNRIs, tricyclic antidepressants or lithium. For fluoxetine, a washout period of two to three weeks is advised before and after treatment with fluoxetine (see PRECAUTIONS, Interactions with Other Medicines).

**Electroconvulsive Therapy**

Concomitant use of tricyclic antidepressants and electroconvulsive therapy should only be undertaken under careful supervision as there is a minimal clinical experience with this combination.

**Central Nervous System Effects**

Many patients with panic disorder experience intensified anxiety symptoms at the start of the treatment with clomipramine. This paradoxical initial increase in anxiety is most pronounced during the first few days of treatment and generally subsides within two weeks.

Owing to their activating effect, tricyclic antidepressants may cause anxiety, feelings of unrest and hyperexcitation in agitated patients and patients with accompanying schizophrenic symptoms. Activation of psychosis has occasionally been observed in patients with schizophrenia receiving tricyclic antidepressants.

In patients with bipolar affective disorders a swing from depression to hypomania or mania is possible. In such cases it may be necessary to withdraw clomipramine and administer drugs to control the mania. After such episodes have subsided, low-dose therapy with clomipramine may be resumed if required.

In predisposed and elderly patients, particularly at night, tricyclic antidepressants may provoke delirious psychoses, which disappear without treatment within a few days of withdrawing the drug.

**Treatment Discontinuation**

Abrupt withdrawal should be avoided because of possible adverse reactions. If the decision has been made to discontinue treatment, medication should be tapered, with recognition that abrupt discontinuation can be associated with certain symptoms (see ADVERSE EFFECTS).
Patient Monitoring
Before initiating treatment with clomipramine, pre-existing hypokalaemia should be treated.

Before starting treatment it is advisable to check the patient’s blood pressure, because individuals with hypotension or a labile circulation may react to the drug with a fall in blood pressure.

The blood count should be monitored during treatment with clomipramine (especially if the patient develops fever, sore throat, or other symptoms which are associated with influenza infection), since isolated cases of agranulocytosis have been associated with the use of tricyclic antidepressants. This is particularly called for during the first few months of therapy and during prolonged treatment.

In patients with known liver disease or a history of liver disease, periodic monitoring of hepatic enzyme levels is recommended (see ADVERSE EFFECTS, Hepatic / Liver).

It is also recommended that patients with known renal impairment be monitored.

Dental Effects
Treatment with tricyclic antidepressants can lead to an increased incidence of dental caries.

Effects on the Eye
Decreased lacrimation and accumulation of mucoid secretions may cause damage to the corneal epithelium in patients with contact lenses.

Anaesthesia
Before general or local anaesthesia, the anaesthetist should be notified that the patient has been receiving clomipramine (see PRECAUTIONS, Interactions with Other Medicines – Alcohol and Other Central Nervous System Depressants).

Lactose
These tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, severe lactase deficiency, sucrase-isomaltase insufficiency or glucose-galactose malabsorption should not take these tablets.

Effects on Fertility
According to the experimental data available, clomipramine has no mutagenic, carcinogenic or teratogenic effects. However, clomipramine has been shown to be embryotoxic in the mouse and rat at the lowest dose tested, which was 4 times the maximum recommended human dose on a body weight basis.

Use in Pregnancy (Category C)
Category C – Definition: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human foetus or neonate without causing malformations. These effects may be reversible. Accompanying text above should be consulted for further details.

Tricyclic antidepressants have not been shown to be associated with an increased incidence of birth defects. However, there is evidence of interference with central monoamine neurotransmission in rats. Care should be taken that there are sound indications for the use of these antidepressants in pregnancy. Experience with clomipramine in pregnancy is limited. Since there have been isolated reports of a possible connection between the use of clomipramine and adverse effects (developmental disorders) on the foetus, treatment with clomipramine should be avoided during pregnancy and only considered if the expected benefits justify the potential risk for the foetus.

Newborn infants whose mothers had taken clomipramine up until delivery showed symptoms such as dyspnoea, cyanosis, lethargy, feeding difficulties, colic, irritability, convulsions, tremor, hypertonia, hypotonia or spasms, during the first hours or days of life. To guard against such symptoms, clomipramine should be gradually withdrawn if at all possible, at least seven weeks before the calculated date of confinement.
Use in Lactation
As clomipramine passes into human milk, babies should be weaned or clomipramine gradually withdrawn.

Use in Children and Adolescents (< 18 years)
The safety and efficacy of clomipramine for the treatment of depression or other psychiatric disorders in children and adolescents aged less than 18 years has not been satisfactorily established. Clomipramine should not be used in this age group for the treatment of depression or other psychiatric disorders. Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are not available.

Carcinogenicity
According to the experimental data available, clomipramine has no carcinogenic effects.

Genotoxicity
According to the experimental data available, clomipramine has no mutagenic effects.

Effects on Ability to Drive or Operate Machinery
Clomipramine may cause blurred vision, somnolence and other central nervous symptoms (see ADVERSE EFFECTS) which may impair the patient's reactions. Patients must therefore be warned against engaging in activities that require quick reactions, such as driving motor vehicles and operating machines. Patients should also be warned that alcohol or other drugs may potentiate these effects (see PRECAUTIONS, Interactions with Other Medicines).

Interactions with Other Medicines
Pharmacodynamic-Related Interactions

MAO Inhibitors
If clomipramine is to be used after treatment with an MAO inhibitor, it is absolutely essential that an interval of at least 14 days should elapse before starting therapy, otherwise severe interactions may occur (e.g. hyperactivity, hypertensive crisis, hyperpyrexia, spasticity, convulsions, coma or death), including those consistent with serotonin syndrome (see PRECAUTIONS, Serotonin Syndrome). The same precaution should be taken when administering a MAO inhibitor after previous treatment with clomipramine tablets. In either instance, medication with clomipramine tablets or with the MAO inhibitor should be started cautiously and the dosage raised stepwise until the optimum response is obtained (see CONTRAINDICATIONS).

There is evidence to suggest that clomipramine may be given as little as 24 hours after a reversible MAO-A inhibitor such as moclobemide, but the two-week washout period must be observed if the MAO-A inhibitor is given after clomipramine has been used. Patients should be monitored for symptoms suggestive of serotonin syndrome (see CONTRAINDICATIONS).

Antihypertensive Agents
Since tricyclic antidepressants may reduce or abolish the antihypertensive effect of clonidine, guanethidine, bethanidine, reserpine and methyldopa, antihypertensive agents with a different mode of action (e.g. beta-blockers) should be used, if necessary.

Sympathomimetic Amines
The cardiovascular effects of sympathomimetic agents (such as adrenaline, noradrenaline, and amphetamine), may be potentiated by tricyclic antidepressants. This includes sympathomimetic amines in nose drops or in local anaesthetic preparations.

Alcohol and Other Central Nervous System Depressants
Tricyclic antidepressants may also increase the effect of alcohol and other central depressant substances (e.g. barbiturates, benzodiazepines or general anaesthetics).

Anticholinergic Agents
When tricyclic antidepressants are given in combination with anticholinergics (including those used to treat patients with Parkinson’s disease), atropine, antihistamines, biperiden or neuroleptics (such as phenothiazines with an anticholinergic action), hyperexcitatory states or delirium may occur, as well as attacks of glaucoma, urinary retention or paralytic ileus.
Serotonergic Agents
Serotonin syndrome can possibly occur when clomipramine is co-administered with serotonergic co-medications such as SSRIs, SNRIs, tricyclic antidepressants or lithium (see PRECAUTIONS, Serotonin Syndrome).

Diuretics
Co-medication of clomipramine with diuretics may lead to hypokalaemia, which in turn increases the risk of QTc prolongation and Torsades de pointes. Therefore hypokalaemia should be treated prior to administration of clomipramine (see PRECAUTIONS, QTc Prolongation).

Benzodiazepines
It might be necessary to lower the dosage of the tricyclic antidepressant if administered concomitantly with alprazolam. No such effects are known to occur in combination with diazepam.

Disulfiram
It might be necessary to lower the dosage of the tricyclic antidepressant if used concomitantly with disulfiram.

Pharmacokinetic-Related Interactions
Clomipramine is predominately eliminated through metabolism. The primary route of metabolism is demethylation to form the active metabolite, N-desmethyliclomipramine, followed by hydroxylation and further conjugation of both N-desmethyliclomipramine and the parent drug. Several cytochrome P450s are involved in the demethylation, mainly CYP3A4, CYP2C19 and CYP1A2. Elimination of both active components is by hydroxylation and this is catalysed by CYP2D6 (see PHARMACOLOGY, Pharmacokinetics – Metabolism).

Cytochrome P450 Enzyme inhibitors
Potential Interactions
Concomitant administration of CYP2D6 inhibitors may lead to an increase in concentration of both active components, up to ~3-fold in patients with a debrisoquine/sparteine extensive metaboliser phenotype, converting them to a poor-metaboliser phenotype. Concomitant administration of CYP1A2, CYP2C19 and CYP3A4 inhibitors is expected to increase clomipramine concentrations and decrease N-desmethyliclomipramine, thus not necessarily affecting the overall pharmacology.

Clomipramine is also an in vitro ($K_i = 2.2 \mu M$) and in vivo inhibitor of CYP2D6 activity (sparteine oxidation) and, therefore, may cause increased concentrations of co-administered compounds that are primarily cleared by CYP2D6 in extensive metabolisers.

MAO Inhibitors
These agents, which are also potent CYP2D6 inhibitors in vivo, such as moclobemide, are contraindicated for co-administration with clomipramine.

Antiarhythmic Agents
Tricyclic antidepressants should not be employed in combination with antiarrhythmic agents of the quinidine type, which are potent inhibitors of CYP2D6.

Selective Serotonin Re-uptake Inhibitors (SSRIs)
SSRIs which are inhibitors of CYP2D6 (such as fluoxetine, paroxetine or sertraline) and of others, including CYP1A2 and CYP2C19 (e.g. fluvoxamine), may also increase plasma concentrations of clomipramine with corresponding adverse effects. Steady-state serum levels of clomipramine increased ~4-fold by co-administration of fluvoxamine and N-desmethyliclomipramine decreased ~2-fold. For fluoxetine, a washout period of two to three weeks is advised before and after treatment with fluoxetine.

Anticonvulsants
Concomitant administration of a tricyclic antidepressant with phenytoin or carbamazepine may lead to elevated serum phenytoin or carbamazepine concentrations. If necessary, the doses of the drugs should be adjusted accordingly.
Neuroleptic Agents
Neuroleptics (e.g. phenothiazines) may result in an increase in the plasma concentration of tricyclic antidepressant agents, a lowered convulsion threshold and seizures. Combination with thioridazine may produce severe cardiac arrhythmias.

Oral antifungal, terbinafine
Co-administration with terbinafine, a strong inhibitor of CYP2D6, may result in increased exposure and accumulation of clomipramine and its N-demethylated metabolite. Therefore, dose adjustments may be necessary when coadministered with terbinafine.

Anticoagulants
Some tricyclic antidepressants may potentiate the anticoagulant effect of coumarin drugs such as warfarin, which may be due to inhibition of their hepatic metabolism (CYP2C9). There is no evidence for the ability of clomipramine to inhibit the metabolism of anticoagulants such as warfarin. However, careful monitoring of plasma prothrombin is advised.

Cimetidine
Since cimetidine is an inhibitor of several P450 enzymes, including CYP2D6 and CYP3A4, and raises the plasma concentration of tricyclic antidepressants, the dosage of the tricyclic agent should be reduced if the two drugs are administered concurrently.

Methylphenidate
By potentially inhibiting their metabolism, methylphenidate may cause the plasma concentration of tricyclic antidepressants to rise and so intensify their antidepressant effect. A dose reduction of the tricyclic antidepressant may be necessary.

Oestrogens
No interaction between chronic oral contraceptive use (15 or 30 µg ethinyl oestradiol daily) and clomipramine (25 mg daily) has been documented. Oestrogens are not known to be inhibitors of CYP2D6, the major enzyme involved in clomipramine clearance, and, therefore, no interaction is expected. Although in a few cases with high dose oestrogen (50 µg daily) and the tricyclic antidepressant imipramine, increased side effects and therapeutic response were noted, it is unclear as to the relevance of these cases to clomipramine and lower dose oestrogen regimens. Monitoring therapeutic response of tricyclic antidepressants at high dose oestrogen regimens (50 µg daily) is recommended and dose adjustments may be necessary.

Cytochrome P450 Enzyme Inducers
Potential Interactions
Concomitant administration of drugs known to induce cytochrome P450 enzymes, particularly CYP3A4, CYP2C19 and/or CYP1A2, may accelerate the metabolism and decrease the efficacy of clomipramine.

CYP3A and CYP2C inducers, such as rifampicin or anticonvulsants (e.g. barbiturates, carbamazepine, phenobarbital and phenytoin), may decrease clomipramine concentrations.

Known inducers of CYP1A2 (e.g. nicotine/components in cigarette smoke) decrease plasma concentrations of tricyclic drugs. In cigarette smokers, clomipramine steady-state plasma concentrations were decreased 2-fold compared to non-smokers (no change in N-desmethyliclomipramine).
ADVERSE EFFECTS

Adverse reactions do not always correlate with plasma drug levels or dose. If severe neurological or psychiatric reactions occur, clomipramine should be withdrawn. Elderly patients are particularly sensitive to anticholinergic, neurological, psychiatric or cardiovascular effects.

Reporting frequencies are described as follows;

- **Very common:** ≥ 10%
- **Common:** ≥ 1 - < 10%
- **Uncommon:** ≥ 0.1 - < 1%
- **Rare:** ≥ 0.01 - < 0.1 %
- **Very rare:** < 0.01%

**Anticholinergic Effects**

- **Very Common:** Dryness of the mouth, sweating, constipation, disorders of visual accommodation, blurred vision, disturbances of micturition.
- **Common:** Hot flushes, mydriasis.
- **Very Rare:** Glaucoma, paralytic ileus, urinary retention.

**Central Nervous System / Psychiatric Effects**

- **Very Common:** Drowsiness, transient fatigue, feelings of unrest, increased appetite.
- **Common:** Confusion accompanied by disorientation and hallucinations (particularly in elderly patients and patients with Parkinson's disease), anxiety states, agitation, sleep disturbances, mania, hypomania, aggressiveness, impaired memory, yawning, depersonalisation, insomnia, nightmares, aggravated depression, impaired concentration.
- **Uncommon:** Activation of psychotic symptoms.

**Neurological Effects**

- **Very Common:** Dizziness, tremor, headache, myoclonus.
- **Common:** Delirium, speech disorders, paraesthesia, muscle weakness, muscle hypertonia.
- **Uncommon:** Convulsions, ataxia.
- **Very Rare:** EEG changes, hyperpyrexia, peripheral neuropathy, neuroleptic malignant syndrome.

**Cardiovascular System**

- **Common:** Postural hypotension, sinus tachycardia, clinically irrelevant ECG changes (e.g. T- and ST-wave changes) in patients of normal cardiac status, palpitations.
- **Uncommon:** Anrythmias, increased blood pressure.
- **Very Rare:** Conduction disorders [e.g. widening of QRS complex, prolonged PR and QTc (QT/RR) intervals, bundle-branch block, Torsades de pointes in association with hypokalaemia], cardiomyopathy, congestive cardiac failure, myocardial infarction, stroke and sudden death.

**Gastrointestinal Tract**

- **Very Common:** Nausea, constipation.
- **Common:** Vomiting, abdominal disorders, diarrhoea, anorexia.

**Hepatic / Liver**

- **Common:** Elevated transaminases, elevated alkaline phosphatase.
- **Very Rare:** Hepatitis with or without jaundice, acute hepatitis, hepatic necrosis.
Dermatological / Skin
Common: Allergic skin reactions (rash, urticaria), photosensitivity, pruritus.
Very Rare: Oedema (local or generalised), hair loss.

Endocrine System and Metabolism
Very Common: Weight gain, disturbances of libido and potency.
Common: Galactorrhoea, breast enlargement.
Very Rare: SIADH (inappropriate antidiuretic hormone secretion syndrome), testicular swelling, parotid swelling.

Hypersensitivity
Very Rare: Allergic alveolitis (pneumonitis) with or without eosinophilia, systemic anaphylactic/anaphylactoid reactions including hypotension.

Haematological / Blood
Very Rare: Leucopenia, agranulocytosis, thrombocytopenia, eosinophilia, purpura.
One case of pancytopenia has been reported.

Sense Organs
Common: Tinnitus, taste perversion.

Withdrawal Symptoms
Common: Although not indicative of addiction, withdrawal symptoms follow abrupt discontinuation of treatment or reduction of the dose: nausea, vomiting, abdominal pain, diarrhoea, insomnia, headache, nervousness, anxiety, dizziness and worsening of psychiatric status.

Bone fractures
Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fracture in patients receiving SSRIs and tricyclic antidepressants.

The mechanism leading to this risk is unknown.

DOSAGE AND ADMINISTRATION

General
The dosage should be determined individually and adapted to the patient’s condition. Doses should be kept as low as possible and increased cautiously, particularly when treating elderly patients, who show a more marked response to clomipramine than patients in intermediate age groups. Note that the plasma concentrations of clomipramine and its active metabolite do not stabilise for 7 to 14 days after commencing treatment and after a dosage change.

During treatment, the efficacy and tolerability of clomipramine must be judged by keeping the patient under close surveillance.

Depression, Obsessive-Compulsive Disorders and Phobias
Commence treatment with 25 mg (one tablet) two or three times daily. Increase the daily dosage stepwise, e.g. 25 mg every few days (depending on how the medication is tolerated) to 100 to 150 mg (four to six tablets). Once a distinct improvement has set in, adjust the daily dosage to a maintenance level averaging 50 to 100 mg (two to four tablets).
Cataplexy Accompanying Narcolepsy
Clomipramine should be given orally in a daily dose of 25–75 mg. Nocturnal medication should only be given in cases where clomipramine does not appear to exacerbate insomnia.

Use in the Elderly
Start treatment with 25 mg (one tablet) daily. Gradually increase the dosage over about ten days to an optimum level of 50 to 75 mg daily. This dose should then be adhered to until the end of treatment.

OVERDOSAGE
Since children react much more sensitively than adults to acute overdosages of tricyclic antidepressants, and since fatalities have been reported, every effort should be made to avoid an overdosage (see Safety Note Concerning Children) which, if it does occur, should be treated with extreme care.

Symptoms
The first signs and symptoms of poisoning with tricyclic antidepressants generally take the form of severe anticholinergic reactions, which set in about ½–2 hours after the drug has been taken. Owing to the delayed absorption (anticholinergic effect), long half-life and enterohepatic recycling of the drug, the patient may be at risk for up to 4–6 days.

The severity of poisoning with tricyclic antidepressants may depend on various factors, such as the amount of the drug absorbed, the time elapsing between its ingestion and the start of treatment, and the patient's age.

The following signs and symptoms may be encountered:
- Central nervous system: drowsiness, stupor, coma, ataxia, restlessness, agitation, mydriasis, enhanced reflexes, muscular rigidity, athetoid and choreoathetoid movements, convulsions. In addition, symptoms consistent with serotonin syndrome (e.g., hyperpyrexia, myoclonus, delirium and coma) may be observed.
- Cardiovascular system: arrhythmias (including Torsades de pointes), tachycardia, conduction disorders, hypotension, shock, heart failure, QTc prolongation; in very rare cases, cardiac arrest.
- Respiratory system: respiratory depression, apnoea, cyanosis.
- Other: vomiting, fever, sweating, and oliguria or anuria may occur.

Treatment
There is no specific antidote and treatment is essentially symptomatic and supportive. Where the drug has been taken by mouth activated charcoal should be administered.

Anyone suspected of receiving an overdose of clomipramine, particularly children, should be immediately hospitalised and kept under close surveillance for at least 72 hours. Severe poisoning with tricyclic antidepressants requires immediate hospitalisation and continuous cardiovascular monitoring for at least 48 hours. In all patients with ECG abnormalities, cardiac function should be kept under close observation for at least another 72 hours even after the ECG tracings have reverted to normal, because relapses may occur.

The following measures should also be taken in cases of overdosage:
- In respiratory failure: intubation and artificial respiration.
- In severe hypotension: place the patient in an appropriate position and give a plasma expander.
- Cardiac arrhythmias must be treated according to the requirements of the case.
- Implantation of a cardiac pacemaker should be considered.
- Low serum potassium and acidosis should be corrected.
- In convulsions, diazepam should be given intravenously. Other anti-convulsants may be required.

Dialysis and haemodialysis are of no use.

Safety Note Concerning Children
Patients should be advised to keep Clomipramine Tablets out of the reach of children.
Contact the Poison Information Centre on 13 11 26 (Australia) for advice on the management of overdose.

PRESENTATION AND STORAGE CONDITIONS

GenRx Clomipramine 25 mg tablets
Round, pale yellow, film coated, biconvex tablets engraved “25” on one side.
Blister packs of 50.
AUST R 73878.

GenRx Clomipramine 25 mg tablets are intended for oral administration.

Each tablet contains 25 mg clomipramine hydrochloride.

In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose, croscarmellose sodium, magnesium stearate, anhydrous colloidal silica, hypromellose, macrogol 3350, titanium dioxide E171 and iron oxide yellow CI77492.

Store below 25°C. Protect from heat and moisture.

POISONS SCHEDULE OF THE MEDICINE

S4: Prescription Only Medicine.

NAME AND ADDRESS OF THE SPONSOR

Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park NSW 2113

GenRx is a registered trade mark of Apotex Pty Ltd.

Date of TGA approval: 17 May 2000

Date of most recent amendment: 30 June 2012